Three People (two women and a man) at the gym doing spinning on indoor bicycles
Three People (two women and a man) at the gym doing spinning on indoor bicycles
Factor VIII levels at 43%, 4 days after infusion
Hypothetical patient and scenario
Factor VIII levels at 43%, 4 days after infusion
Hypothetical patient and scenario

Factor UP! with an established safety profile

In XTEND-1 and XTEND-Kids, people taking ALTUVIIIO had:

0
inhibitors
0
serious allergic reaction
Although no inhibitors were found, and no serious allergic reactions occurred in clinical studies, inhibitors and serious allergic reactions are possible with ALTUVIIIO.

In 159 people taking ALTUVIIIO in the XTEND-1 study:

  • 21% of people had headache (33 people)
  • 16% of people had joint pain (26 people)
  • 6% of people had back pain (9 people)
  • 21% of people had headache (33 people)
  • 16% of people had joint pain (26 people)
  • 6% of people had back pain (9 people)

In 67 children taking ALTUVIIIO in the XTEND-Kids study:

1% of children had headache (1 child)

1% of children had headache (1 child)

Find your CoRe Manager and connect today!
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.
Altuviiio branding design